The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Open accessAbstract
BACKGROUND: The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy. We prospectively compared the effect of genotype-guided dosing with that of standard dosing on anticoagulation control in patients starting warfarin therapy. METHODS: We conducted a multicenter, randomized, controlled trial involving patients with atrial fibrillation or venous thromboembolism. Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days. Patients in the control (standard dosing) group received a 3-day loading-dose regimen. After the initiation period, the treatment of all patients was managed according to routine clinical practice. The primary outcome measure was the percentage of time in the therapeutic range of 2.0 to 3.0 for the international normalized ratio (INR) during the first 12 weeks after warfarin initiation. RESULTS: A total of 455 patients were recruited, with 227 randomly assigned to the genotype-guided group and 228 assigned to the control group. The mean percentage of time in the therapeutic range was 67.4% in the genotype-guided group as compared with 60.3% in the control group (adjusted difference, 7.0 percentage points; 95% confidence interval, 3.3 to 10.6; P<0.001). There were significantly fewer incidences of excessive anticoagulation (INR ≥4.0) in the genotype-guided group. The median time to reach a therapeutic INR was 21 days in the genotype-guided group as compared with 29 days in the control group (P<0.001). CONCLUSIONS: Pharmacogenetic-based dosing was associated with a higher percentage of time in the therapeutic INR range than was standard dosing during the initiation of warfarin therapy. (Funded by the European Commission Seventh Framework Programme and others; ClinicalTrials.gov number, NCT01119300.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Self-citationA Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin
Hylek, E. M., & Singer, D. E. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-11-199406010-00001 · Cited by 919
Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F. S., May, H. T., Samuelson, K. M., Muhlestein, J. B., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.737312 · Cited by 727
Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 647
Self-citationThe largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
Self-citationCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Pharmacogenetics of warfarin: current status and future challenges
Wadelius, M., & Pirmohamed, M. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500417 · Cited by 330
Self-citationPerera, M. A., Cavallari, L. H., Limdi, N. A., Gamazon, E. R., Konkashbaev, A., Daneshjou, R., Pluzhnikov, A., Crawford, D. C., Wang, J., Liu, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60681-9 · Cited by 276
Self-citationAnderson, J. L., Horne, B. D., Stevens, S. M., Woller, S. C., Samuelson, K. M., Mansfield, J. W., Robinson, M., Barton, S., Brunisholz, K., Mower, C. P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.070920 · Cited by 229
Kovacs, M. J., Rodger, M., Anderson, D. R., Morrow, B., Kells, G., Kovacs, J., Boyle, E., & Wells, P. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-9-200305060-00007 · Cited by 223
Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing
Lenzini, P., Wadelius, M., Kimmel, S., Anderson, J. L., Jorgensen, A. L., Pirmohamed, M., Caldwell, M. D., Limdi, N., Burmester, J. K., Dowd, M. B., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.13 · Cited by 216
Self-citationHillman, M. A., Wilke, R. A., Yale, S. H., Vidaillet, H. J., Caldwell, M. D., Glurich, I., Berg, R. L., Schmelzer, J., & Burmester, J. K. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.3.137 · Cited by 196
Jorgensen, A. L., FitzGerald, R. J., Oyee, J., Pirmohamed, M., & Williamson, P. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044064 · Cited by 171
Self-citationvan Schie, R. M., Wadelius, M., Kamali, F., Daly, A. K., Manolopoulos, V. G., de Boer, A., Barallon, R. V., Verhoef, T. I., Kirchheiner, J., Haschke‐Becher, E., et al. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.125 · Cited by 148
Self-citationFinkelman, B. S., Gage, B. F., Johnson, J. A., Brensinger, C. M., & Kimmel, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.08.643 · Cited by 132
Yang, J., Chen, Y., Li, X., Wei, X., Chen, X., Zhang, L., Zhang, Y., Xu, Q., Wang, H., Li, Y., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.151 · Cited by 96
Avery, P. J., Jorgensen, A., Hamberg, A., Wadelius, M., Pirmohamed, M., & Kamali, F. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.186 · Cited by 78
Self-citationThe Future of Warfarin Pharmacogenetics in under-represented Minority Groups
Cavallari, L. H., & Perera, M. A. (2012) · Future Cardiology · doi:10.2217/fca.12.31 · Cited by 71
Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms
Daly, A. K. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1013-9 · Cited by 69
Self-citationOptimal loading dose of warfarin for the initiation of oral anticoagulation
Mahtani, K. R., Heneghan, C. J., Nunan, D., Bankhead, C. R., Keeling, D. M., Ward, A. M., Harrison, S., Roberts, N. W., Hobbs, R. F., & Perera, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008685.pub2 · Cited by 40
Cited by
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Horlocker, T. T., Vandermeuelen, E., Kopp, S. L., Gogarten, W., Leffert, L. R., & Benzon, H. T. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000763 · Cited by 932
Johnson, J., Caudle, K., Gong, L., Whirl‐Carrillo, M., Stein, C., Scott, S., Lee, M., Gage, B., Kimmel, S., Perera, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.668 · Cited by 716
Self-citationZhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Metadata
- Authors
- Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., Zhang, J. E., Leathart, J. B., Kohnke, H., Maitland-van der Zee, A. H., Williamson, P. R., Daly, A. K., Avery, P., Kamali, F., & Wadelius, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-12
- Volume
- 369
- Issue
- 24
- Pages
- 2294-2303
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157839219
- Cited by
- 811
- References
- 26
- FWCI
- 115.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.